rs16860717
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_015039.4(NMNAT2):c.651+6993G>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0391 in 152,232 control chromosomes in the GnomAD database, including 143 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.039 ( 143 hom., cov: 32)
Consequence
NMNAT2
NM_015039.4 intron
NM_015039.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.333
Publications
0 publications found
Genes affected
NMNAT2 (HGNC:16789): (nicotinamide nucleotide adenylyltransferase 2) This gene product belongs to the nicotinamide mononucleotide adenylyltransferase (NMNAT) enzyme family, members of which catalyze an essential step in NAD (NADP) biosynthetic pathway. Unlike the other human family member, which is localized to the nucleus, and is ubiquitously expressed; this enzyme is cytoplasmic, and is predominantly expressed in the brain. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.113 is higher than 0.05.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| NMNAT2 | ENST00000287713.7 | c.651+6993G>C | intron_variant | Intron 8 of 10 | 1 | NM_015039.4 | ENSP00000287713.6 | |||
| NMNAT2 | ENST00000294868.8 | c.636+6993G>C | intron_variant | Intron 8 of 10 | 1 | ENSP00000294868.4 | ||||
| NMNAT2 | ENST00000464047.1 | n.133+6993G>C | intron_variant | Intron 1 of 3 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0391 AC: 5950AN: 152114Hom.: 142 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
5950
AN:
152114
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.0391 AC: 5958AN: 152232Hom.: 143 Cov.: 32 AF XY: 0.0401 AC XY: 2982AN XY: 74426 show subpopulations
GnomAD4 genome
AF:
AC:
5958
AN:
152232
Hom.:
Cov.:
32
AF XY:
AC XY:
2982
AN XY:
74426
show subpopulations
African (AFR)
AF:
AC:
1183
AN:
41548
American (AMR)
AF:
AC:
825
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
AC:
167
AN:
3472
East Asian (EAS)
AF:
AC:
401
AN:
5186
South Asian (SAS)
AF:
AC:
582
AN:
4824
European-Finnish (FIN)
AF:
AC:
272
AN:
10594
Middle Eastern (MID)
AF:
AC:
11
AN:
294
European-Non Finnish (NFE)
AF:
AC:
2420
AN:
68004
Other (OTH)
AF:
AC:
96
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
294
588
883
1177
1471
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
84
168
252
336
420
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
389
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.